Status:
COMPLETED
ProQuad Dose Selection Study (V221-011)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Measles
Mumps
Eligibility:
All Genders
12-23 years
Phase:
PHASE2
Brief Summary
A Study comparing three different doses of ProQuad to concomitant administration of M-M-R II and PUVV (Process Upgrade Varicella Vaccine) vaccines.
Eligibility Criteria
Inclusion
- In good health
- Negative clinical history of measles, mumps, rubella, varicella, and zoster
Exclusion
- Previous receipt of measles, mumps, rubella and/or varicella vaccine either alone or in combination
- Any immune impairment or deficiency
- Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to vaccination
- Vaccination with an inactive vaccine with in the past 14 days
- Vaccination with a live vaccine within the past 30 days
- Immune globulin or any blood product administered in the past 3 months
Key Trial Info
Start Date :
April 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2000
Estimated Enrollment :
1551 Patients enrolled
Trial Details
Trial ID
NCT00986232
Start Date
April 1 1999
End Date
September 1 2000
Last Update
April 10 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.